Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.52 |
| ▸ | DBH | P09172 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129275 | 0.80 | HSP90AA1 (0.46) | CXCR2CA2CA4ALDH1A1MAPT | |
| SCHEMBL122963 | 0.80 | ALDH1A1 (0.60) | DBHMMP2CA2KDM4EPOLB | |
| SCHEMBL3440828 | 0.77 | ALDH1A1 (0.56) | CXCR2DBHMMP2CA2KDM4E | |
| SCHEMBL49313 | 0.77 | — | — | |
| SCHEMBL15059320 | 0.77 | — | — | |
| SCHEMBL29573828 | 0.77 | — | — | |
| Formaldehyde SCHEMBL674875 | 0.76 | ALDH1A1 (0.47) | CXCR2DBHMMP2CA2KDM4E | |
| SCHEMBL10560599 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL21820164 | 0.75 | — | — | |
| SCHEMBL38651119 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0267378-B1 | TROPOLONE DERIVATIVES AS AN ANTI-MYCOPLASMA AGENT | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-11-04 | — | — | EP | claimed |
| EP-0267378-A2 | Tropolone derivatives as an anti-mycoplasma agent | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-05-18 | — | — | EP | claimed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076938-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021041776-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-0267378-B1 | TROPOLONE DERIVATIVES AS AN ANTI-MYCOPLASMA AGENT | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| US-4950686-A | Anti-mycoplasma agent | SHIONOGI & CO., LTD. (JP) | 1990-08-21 | — | — | US | disclosed |
| EP-0267378-A2 | Tropolone derivatives as an anti-mycoplasma agent | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TXNRD1, SDHB | CXCR2 4273/4885DBH 122/4885MMP2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.